Novo Inks $600M Deal with Metaphore to Develop Next-Gen Obesity Drugs

As competition with Eli Lilly heats up, Novo Nordisk has partnered with Flagship’s Metaphore Biotechnologies to take biomimicry approach to GLP-1s.